Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIN1001 with and without chemotherapy in advanced solid tumors
NCT03950570Phase 2Completed
- Sponsor
- Orinove Inc.
- Start
- May 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ORIN1001 in solid tumor and breast cancer (6 arms), sponsored by Orinove Inc. Primary endpoints: Safety of MTD/RP2D of single-agent daily ORIN1001, Safety of MTD/RP2D of ORIN1001 in combination with paclitaxel and 2 more. Started May 2019; status: completed.
02
Drugs
ORIN1001
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT03950570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950570.